Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What are the unmet needs in the treatment of HR-positive, HER2-negative early breast cancer and what factors influence the likelihood of recurrence? (0:12)
- Could you tell us a little about the aims, design and findings of the MonarchE clinical trial? (1:15)
- What is the clinical significance of these findings and how are they likely to impact on future clinical practice? (2:45)
- What other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? (4:09)
- What will be the next steps in the clinical development of abemaciclib in breast cancer therapy? (6:02)
Speaker Disclosures: Stephen Johnston has provided consultancy for Novartis, Pfizer, Eli Lilly, Puma Biotechnology; has received speaker honoraria from Eisai, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; and has received research funding for his institution from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. The MonarchE trial was sponsored by Eli Lilly and Company.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!